LONDON, June 23, 2016 /PRNewswire/ --
Joleen M Hubbard, Axel Grothey, Oncology & Hematology Review, 2016;12(1):41-6 http://doi.org/10.17925/OHR.2016.12.01.41
Recently in Oncology & Hematology Review, the peer-reviewed journal from touchONCOLOGY, Joleen M Hubbard and Axel Grothey, introduce cancer stem cells (CSCs) as a subpopulation of phenotypically distinct cancer cells that may play an important role in tumor pathogenesis. The gastrointestinal (GI) system provides a good example for investigation of the role of CSCs in tumor proliferation; GI CSCs are suitable for study due to their abundance, proliferative potential, and consistent structural arrangement that is maintained under tightly controlled signaling pathways. GI stem cells have a long lifespan and this, combined with their rapid turnover, may predispose them to forming CSCs. Alternative possible sources of GI CSCs include differentiated intestinal cells, bone marrow, and cancer cells. Therapies that specifically target CSCs present an exciting opportunity to treat patients with cancer. Enhanced understanding of CSC markers, such as CD133, CD44, and epithelial cell adhesion molecule (EpCAM), may facilitate development of therapies that target them. Among the stemness pathways that have been targeted are Wnt/?-catenin, STAT, Notch, and Nanog.
(Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )
The full peer-reviewed, open-access article is available here:
http://doi.org/10.17925/OHR.2016.12.01.41
Joleen M Hubbard receives research support from Boston Biomedical. Axel Grothey has nothing to disclose in relation to this article.
About touchONCOLOGY.com: touchONCOLOGY (a division of Touch Medical Media) publishesOncology & Hematology Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology and hematology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
www.touchONCOLOGY.com
For inquires please contact: Nicola Cartridge - Managing Editor [email protected] Providing practical opinion to support best practice for busy healthcare professionals.
SOURCE touchONCOLOGY.com
Advertisement
Joleen M Hubbard, Axel Grothey, Oncology & Hematology Review, 2016;12(1):41-6 http://doi.org/10.17925/OHR.2016.12.01.41
Advertisement
Recently in Oncology & Hematology Review, the peer-reviewed journal from touchONCOLOGY, Joleen M Hubbard and Axel Grothey, introduce cancer stem cells (CSCs) as a subpopulation of phenotypically distinct cancer cells that may play an important role in tumor pathogenesis. The gastrointestinal (GI) system provides a good example for investigation of the role of CSCs in tumor proliferation; GI CSCs are suitable for study due to their abundance, proliferative potential, and consistent structural arrangement that is maintained under tightly controlled signaling pathways. GI stem cells have a long lifespan and this, combined with their rapid turnover, may predispose them to forming CSCs. Alternative possible sources of GI CSCs include differentiated intestinal cells, bone marrow, and cancer cells. Therapies that specifically target CSCs present an exciting opportunity to treat patients with cancer. Enhanced understanding of CSC markers, such as CD133, CD44, and epithelial cell adhesion molecule (EpCAM), may facilitate development of therapies that target them. Among the stemness pathways that have been targeted are Wnt/?-catenin, STAT, Notch, and Nanog.
(Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )
The full peer-reviewed, open-access article is available here:
http://doi.org/10.17925/OHR.2016.12.01.41
Joleen M Hubbard receives research support from Boston Biomedical. Axel Grothey has nothing to disclose in relation to this article.
About touchONCOLOGY.com: touchONCOLOGY (a division of Touch Medical Media) publishesOncology & Hematology Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology and hematology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
www.touchONCOLOGY.com
For inquires please contact: Nicola Cartridge - Managing Editor [email protected] Providing practical opinion to support best practice for busy healthcare professionals.
SOURCE touchONCOLOGY.com
